【摘要】 目的研究探讨小剂量丙戊酸镁联合帕利哌酮缓释片对精神分裂症治疗疗效及脑源性神经营养因子(BDNF)、胶质细胞源性神经营养因子(GDNF)水平的影响。方法以前瞻性分析的方法收集2018年2月～2020年2月期间玉林市退役军人医院收治的精神分裂症患者97例,并以随机数表法分为观察组(51例)和对照组(46例),对照组给予帕利哌酮缓释片治疗,观察组采用小剂量丙戊酸镁联合帕利哌酮缓释片治疗。对两组患者的临床疗效、阳性与阴性症状量表(PANSS)、血清学指标水平、社会行为能力评分、不良反应发生率等进行统计对比。结果观察组治疗总有效率为88.24%(45/51),高于对照组患者为71.74%(33/46),差异有统计学意义(P <0.05)。治疗后观察组PANSS量表各项评分均低于对照组,BDNF、GDNF水平值均高于对照组,差异有统计学意义(P <0.05)。治疗后观察组患者的大体功能评定量表(GAF)评分高于对照组,社会功能缺陷筛选表(SDSS)、攻击行为量表(MOAS)评分低于对照组,差异均有统计学意义(P <0.05)。治疗期间观察组、对照组不良反应发生率分别为15.69%(8/51)、10.87%(5/46),差异无统计学意义(P> 0.05)。结论小剂量丙戊酸镁联合帕利哌酮缓释片对精神分裂症患者治疗效果显著,能够改善患者各项症状,控制患者的攻击行为,提升患者社会功能,提升血清BDNF、GDNF水平,治疗安全性良好。更多还原

【Abstract】 Objective To study the effect of low-dose magnesium valproate combined with paliperidone sustained-release tablets on the therapeutic effect of schizophrenia and the levels of brain-derived neurotrophic factor(BDNF)and glial cell-derived neurotrophic factor(GDNF).Methods 97 schizophrenic patients in our hospital from February 2018 to February 2020 were randomly divided into study group(51 cases)and control group(46 cases).The control group was treated with paliperidone sustained-release tablets,and the study group was treated with low-dose magnesium valproate combined with paliperidone sustained-release tablets.The clinical efficacy,positive and negative symptom scale(PANSS),serological index level,social behavior ability score and incidence of adverse reactions were compared between the two groups. Results The total effective rate of the study group was 88.24%(45/51),which was higher than 71.74%(33/46)of the control group(P < 0.05).After treatment,the scores of PANSS in the study group were higher than those in the control group(P < 0.05).After treatment,the levels of BDNF and GDNF in the study group were higher than those in the control group(P < 0.05).After treatment,the scores of general function assessment scale(GAF)in the study group were higher than those in the control group,while the scores of social function defect screening scale(SDSS)and aggressive behavior scale(moas)in the study group were lower than those in the control group(P < 0.05).During the treatment,the incidence of adverse reactions in the study group and the control group were 15.69%(8/51)and 10.87%(5/46)(P >0.05).Conclusion Small dose of magnesium valproate combined with paliperidone sustained-release tablets has significant therapeutic effect on schizophrenia patients,which can improve the symptoms of patients,control the aggressive behavior of patients,improve the social function of patients,and improve the levels of serum BDNF and GDNF.The treatment is safe and worthy of clinical promotion.更多还原